Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics and schizophrenia.

Adriana Foster1, Del D Miller, Peter F Buckley

  • 1Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA 30912, USA. afoster@mcg.edu <afoster@mcg.edu>

The Psychiatric Clinics of North America
|August 28, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biological insights into schizophrenia from ancestrally diverse populations.

Nature·2026
Same author

Can training clinicians in emotional awareness using virtual patient interactions improve the therapeutic alliance with psychiatric outpatients and reduce suicidal outcomes?

Psychiatry research·2025
Same author

Latent class analysis of symptoms across schizophrenia, schizoaffective disorder, and bipolar I disorder.

medRxiv : the preprint server for health sciences·2025
Same author

CONNECT Platform to Increase Diverse Engagement and Enrollment in Cardiovascular Clinical Research: Rationale, Design, and Lessons Learned in Early Implementation.

Journal of the American Heart Association·2025
Same author

From Dialogue to Action: Community Recommendations for Inclusive Research Participation Among Underrepresented Populations.

Health expectations : an international journal of public participation in health care and health policy·2025
Same author

CEASE Tobacco Cessation Program: Validation of Self-Rated Quit with Fagerstrom Test for Nicotine Dependence.

Global journal of cardiovascular diseases·2025
Same journal

Digital Mental Health: Progress but not Perfection.

The Psychiatric clinics of North America·2026
Same journal

Advances in Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

The Future of Digital Mental Health: A Literature Review.

The Psychiatric clinics of North America·2026
Same journal

Assessment and Treatment of Posttraumatic Stress Disorder via Digital Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

Treatment of Obsessive-Compulsive Disorder via Mental Health Technology.

The Psychiatric clinics of North America·2026
Same journal

Digital Mental Health Treatments for Depression.

The Psychiatric clinics of North America·2026
See all related articles

Pharmacogenetic analysis can predict antipsychotic medication efficacy and side effects in schizophrenia patients. This genetic approach may guide future personalized treatment strategies for improved outcomes and reduced adverse events.

Area of Science:

  • Pharmacology
  • Genetics
  • Psychiatry

Background:

  • Schizophrenia treatment relies on antipsychotic medications.
  • Current antipsychotics have variable efficacy and side effect profiles.
  • Genetic factors are increasingly recognized as influencing drug response.

Purpose of the Study:

  • To explore the predictive role of pharmacogenetics in antipsychotic treatment for schizophrenia.
  • To assess the potential of genetic analysis in forecasting medication efficacy and adverse events.

Main Methods:

  • Review of emergent pharmacogenetic studies.
  • Analysis of genetic markers associated with antipsychotic response.
  • Evaluation of genetic links to side effects like weight gain, metabolic abnormalities, and tardive dyskinesia.

Related Experiment Videos

Main Results:

  • Pharmacogenetic studies suggest genetic analysis can predict antipsychotic efficacy.
  • Evidence indicates genetic factors influence side-effect profiles, including metabolic changes and tardive dyskinesia.
  • Genetic status may predict individual patient response and risk of adverse events.

Conclusions:

  • Pharmacogenetics offers a promising avenue for personalized antipsychotic selection in schizophrenia.
  • Future treatments may utilize genetic profiling to optimize clinical response and minimize side effects.
  • Targeted pharmacogenetic approaches could revolutionize schizophrenia treatment strategies.